The marijuana rescheduling process under the Controlled Substances Act, shifting cannabis from Schedule I to Schedule III, remains stalled at the DEA following HHS's August 2023 scientific recommendation and the agency's May 2024 proposed rule. President Trump's December 2025 executive order directed the DOJ to complete it expeditiously, yet no substantive updates have emerged three months later, prompting Rep. Steve Cohen's March 27 letter demanding a timeline from AG Pam Bondi and DEA Administrator Terry Cole amid missed deadlines. Trader consensus reflects uncertainty from administrative delays, potential Section 811 fast-tracking, ongoing lawsuits challenging related programs, and no scheduled hearings or publication date, with congressional pressure as the key near-term catalyst.
Resumo experimental gerado por IA com dados do Polymarket · Atualizado$285,678 Vol.

30 de junho
13%

31 de dezembro
40%
$285,678 Vol.

30 de junho
13%

31 de dezembro
40%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The marijuana rescheduling process under the Controlled Substances Act, shifting cannabis from Schedule I to Schedule III, remains stalled at the DEA following HHS's August 2023 scientific recommendation and the agency's May 2024 proposed rule. President Trump's December 2025 executive order directed the DOJ to complete it expeditiously, yet no substantive updates have emerged three months later, prompting Rep. Steve Cohen's March 27 letter demanding a timeline from AG Pam Bondi and DEA Administrator Terry Cole amid missed deadlines. Trader consensus reflects uncertainty from administrative delays, potential Section 811 fast-tracking, ongoing lawsuits challenging related programs, and no scheduled hearings or publication date, with congressional pressure as the key near-term catalyst.
Resumo experimental gerado por IA com dados do Polymarket · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions